Nintedanib Accord (Nintedanib)

Nintedanib blocks several receptor tyrosine kinases—VEGFR, FGFR and PDGFR—thereby reducing fibroblast proliferation, extracellular matrix formation, and new blood‑vessel growth. This dual antifibrotic and anti‑angiogenic activity underlies its therapeutic effect in lung fibrosis and selected cancers.

The prescribed dose of Nintedanib Accord is determined by the treating physician based on the specific indication, patient characteristics, and clinical response. Dosage information is provided in the product label and should be followed exactly as directed by a qualified healthcare professional.

Safety data for Nintedanib Accord in pregnancy and lactation are limited. It should only be used when the potential benefit justifies the possible risk to the fetus or infant. Women of child‑bearing potential should use effective contraception during treatment and for a period after discontinuation as advised by their clinician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

The primary alternative for idiopathic pulmonary fibrosis is pirfenidone, another antifibrotic agent. While both slow disease progression, nintedanib targets a broader range of tyrosine kinases, which may offer additional benefits in certain cancers. Choice between them depends on patient tolerance, comorbidities, drug‑interaction profile and physician judgment.

Nintedanib Accord should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid or excessively hot environments.

Nintedanib Accord is taken orally, usually with food to reduce gastrointestinal discomfort. The tablets should be swallowed whole with a full glass of water and not crushed or chewed. Administration timing and any dose adjustments are determined by the prescribing clinician.

Serious risks include elevated liver enzymes, significant bleeding, cardiovascular events such as myocardial infarction, severe infections, gastrointestinal perforation, and rare but severe skin reactions like Stevens‑Johnson syndrome. Patients should report any unusual symptoms promptly and undergo regular laboratory monitoring as advised.

Nintedanib Accord is contraindicated in patients with known hypersensitivity to nintedanib or any of its excipients. Caution is advised for individuals with severe hepatic impairment, uncontrolled bleeding disorders, or those receiving strong CYP3A4 inhibitors. Pregnant or nursing women should only use it when the benefit outweighs potential risks.